WaveMan
WaveMan · Company
SLDB · Solid Biosciences Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SLDB Solid Biosciences (SLDB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001707502
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
99
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · no price filed

What the filings say about SLDB

Insiders, 180 days
-$24.6K net sold
1 seller · 100% of sales under a 10b5-1 plan

Solid Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Solid Biosciences Inc. insiders sold a net $24.6K of stock across 70 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Brooks Gabriel
Chief Medical Officer
SELL
2026-10-20 SECtraded 2026-10-19
4,374
$24.6K
-7.6%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Feb 18, 2026.
  • The trade is 4.5% of the 97,241 shares held after it.
  • No other insider sold within 30 days.
  • 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Brooks Gabriel sold about $24.6K of SLDB under a 10b5-1 plan on Oct 19, 2026; 99 funds added in the latest 13F quarter.
Cumbo Alexander
President and CEO
SELL
2026-02-18 SEC
16,644
$96.9K
+0.7%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Feb 4, 2026.
  • The trade is 7.1% of the 235,405 shares held after it.
  • 6 other insiders sold within 30 days.
  • 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Cumbo Alexander sold about $96.9K of SLDB on Feb 18, 2026; 6 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.
Hanrahan Jessie
Chief Regulatory Officer
SELL
2026-02-18 SEC
4,134
$24.1K
+0.7%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Feb 4, 2026.
  • The trade is 5.6% of the 74,318 shares held after it.
  • 6 other insiders sold within 30 days.
  • 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Regulatory Officer Hanrahan Jessie sold about $24.1K of SLDB on Feb 18, 2026; 6 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.
Ganot Ilan
Director
SELL
2026-02-18 SEC
2,658
$15.5K
+0.7%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Feb 4, 2026.
  • The trade is 9.7% of the 27,474 shares held after it.
  • 6 other insiders sold within 30 days.
  • 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ganot Ilan sold about $15.5K of SLDB on Feb 18, 2026; 6 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.
Herzich Paul
Chief Technology Officer
SELL
2026-02-18 SEC
3,616
$21.0K
+0.7%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Feb 4, 2026.
  • The trade is 5.0% of the 72,638 shares held after it.
  • 6 other insiders sold within 30 days.
  • 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Herzich Paul sold about $21.0K of SLDB on Feb 18, 2026; 6 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.
70 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 65 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$24.6K over 180 days
-$24.6K over 90 days
more than 59% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
99 funds bought in last quarter
more than 68% of Pharma & Biotech
Revenue
-40.6% year over year
below 77% of Pharma & Biotech
Margin
-2153.8% net margin
below 92% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
19.6% of the float short (float per yahoo 2026-10-26) · 7.7 days to cover · settled 2026-09-30
more than 78% of Pharma & Biotech
What changed in the last 30 days
Oct 20Chief Medical Officer Brooks Gabriel sold $24.6K under a 10b5-1 plan (Oct 19)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch SLDB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+5.0%12M
-30%+12%+55%+98%2025-102025-122026-022026-042026-062026-082026-10 2026-02-02 · Cumbo Alexander sold $516.9K2026-02-04 · Cumbo Alexander sold $315.0K2026-02-02 · Howton David T sold $243.2K2026-02-02 · Brooks Gabriel sold $182.5K2026-02-02 · Tan Kevin sold $172.8K2026-02-02 · Hanrahan Jessie sold $170.9K2026-02-02 · Herzich Paul sold $169.1K2026-02-04 · Howton David T sold $121.7K2026-02-18 · Cumbo Alexander sold $96.9K2026-02-04 · Tan Kevin sold $95.2K2026-02-04 · Brooks Gabriel sold $81.2K2026-02-04 · Hanrahan Jessie sold $79.5K2026-02-04 · Herzich Paul sold $70.2K2025-12-03 · Cumbo Alexander sold $55.2K2026-02-04 · Ganot Ilan sold $46.4K2026-02-18 · Howton David T sold $43.5K2026-02-18 · Tan Kevin sold $31.5K2026-01-13 · Tan Kevin sold $30.1K2025-12-03 · Howton David T sold $25.2K2026-10-19 · Brooks Gabriel sold $24.6K2026-02-18 · Hanrahan Jessie sold $24.1K2025-12-03 · Hanrahan Jessie sold $22.9K2026-02-18 · Herzich Paul sold $21.0K2026-02-18 · Ganot Ilan sold $15.5K2025-12-03 · Herzich Paul sold $13.8K2025-11-10 · Ganot Ilan sold $13.5K2026-01-05 · Ganot Ilan sold $5.7K2026-01-28 · Ganot Ilan sold $1.3K2026-02-18 · Brooks Gabriel sold $0
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SLDB: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
12,036,126 sh
$120.2M
PERCEPTIVE ADVISORS LLC
11,906,646 sh
$118.9M
Bain Capital Life Sciences Investors, LLC
9,808,819 sh
$98.0M
Siren, L.L.C.
7,690,405 sh
$76.8M
BlackRock, Inc.
6,934,248 sh
$69.3M

Congress trades in SLDB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SLDB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

SLDB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Franklin Biotechnology Discovery Fund
$11.4M position · as of 2026-07-31
1.0%
Virtus Biotech Clinical Trials Etf
$350.9K position · as of 2026-07-31
0.8%
Columbia Variable Portfolio - Small Company Growth Fund
$1.2M position · as of 2026-06-30
0.5%
Select Biotechnology Portfolio
$19.1M position · as of 2026-05-31
0.4%
Invesco Dorsey Wright SmallCap Momentum ETF
$1.4M position · as of 2026-05-31
0.3%
Columbia Small Cap Growth Fund
$10.8M position · as of 2026-05-31
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
2 active
1
Phase 3
1 active
1
Not applicable
0 active
2
Multi-phase
2 active
What changed recently
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
2026-10-16 · Completion moved 2026-10-15 → 2026-11-30
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.2M
$7.8M
$2.5M
+5%
n/a
2024
$4.9M
$3.5M
$2.3M
-26%
n/a
2023
$918.6K
$862.4K
$1.2M
+14%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $24.6K sold by insiders over 180 days, 99 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SLDB financials

Revenue growth
-40.6%
XBRL, annual
Net margin
-2153.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2020-01-01 to 2020-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$187.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-65.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-56.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-63.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-29.6%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/an/a$8.1M
Operating income-$179.2M-$129.7M-$104.3M-$106.5M
Net income-$174.3M-$124.7M-$96.0M-$86.0M
EPS (diluted)-1.99-3.06-4.83-10.10
Operating cash flow-$156.3M-$100.0M-$94.2M-$98.0M
Cash$59.9M$80.2M$74.0M$155.4M
SEC XBRL, fiscal years, as known on 2026-10-27

SLDB Stock Sonar score 5/7 axes

Find similar shapesCompare

SLDB ranks highest on institutional and government (68th percentile) and profitability (42nd), and lowest on insider conviction (1st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
42
Inputs
  • Return on equity-65.5% · 45 pct, sector of 545
  • Return on assets-56.8% · 40 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-63.3% · 40 pct, sector of 576
Growth
23
Inputs
  • Revenue growth, YoY-40.6% · 23 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
0
Inputs
  • Net Form 4 buying (codes P and S), 180dno Form 4 purchase or sale (code P or S) in 180 days
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
68
Inputs
  • Funds adding, latest quarter99 · 68 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
39
Inputs
  • Short interest, % of float+19.6% · 16 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+8.3% · 62 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SLDB filings, in plain words

Are Solid Biosciences insiders buying or selling SLDB?

In the 180 days to 2026-10-27, Solid Biosciences insiders were net sellers, a net $24.6K across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-27, Solid Biosciences insiders were net sellers of SLDB, a net $24.6K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies